---
title: "GSK plc (GSK.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GSK.US.md"
symbol: "GSK.US"
name: "GSK plc"
industry: "Pharmaceuticals"
datetime: "2026-05-20T04:29:54.545Z"
locales:
  - [en](https://longbridge.com/en/quote/GSK.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GSK.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GSK.US.md)
---

# GSK plc (GSK.US)

## Company Overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.gsk.com](https://www.gsk.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.40)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 42 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.65% |  |
| Net Profit YoY | 93.20% |  |
| P/B Ratio | 4.35 |  |
| Dividend Ratio | 3.53% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 102415443719.68 |  |
| Revenue | 44108282272.26 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 36.42% | A |
| Profit Margin | 17.78% | A |
| Gross Margin | 75.45% | A |
| Revenue YoY | 8.65% | B |
| Net Profit YoY | 93.20% | A |
| Total Assets YoY | 5.48% | C |
| Net Assets YoY | 29.96% | A |
| Cash Flow Margin | 132.73% | B |
| OCF YoY | 8.65% | B |
| Turnover | 0.53 | C |
| Gearing Ratio | 72.29% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - GSK plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.65%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "93.20%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.35",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.53%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "102415443719.68",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "44108282272.26",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "36.42%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "17.78%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "75.45%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "8.65%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "93.20%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.48%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "29.96%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "132.73%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "8.65%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.53",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "72.29%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 13.26 | 19/190 | 19.14 | 15.68 | 13.57 |
| PB | 4.42 | 144/190 | 4.98 | 4.41 | 4.19 |
| PS (TTM) | 2.36 | 67/190 | 2.51 | 2.24 | 1.93 |
| Dividend Yield | 3.47% | 8/190 | 4.06% | 3.49% | 3.25% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-17T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 13% |
| Overweight | 1 | 13% |
| Hold | 5 | 63% |
| Sell | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 51.05 |
| Highest Target | 70.00 |
| Lowest Target | 47.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GSK.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GSK.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GSK.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GSK.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**